US · 1 sources covering this

Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

The United States plans significant tariffs on imported generic medicines. These duties will rise to 200% in the coming years. Dr Reddy's Laboratories anticipates higher medicine prices for American consumers. Shifting manufacturing to the US is currently considered impractical by the company. India faces substantial exposure as a major generic medicine exporter to the US.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

Times of IndiaLean R·2h ago
Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's
The United States plans significant tariffs on imported generic medicines. These duties will rise to 200% in the coming years. Dr Reddy's Laboratories anticipates higher medicine prices for American consumers. Shifting manufacturing to the US is currently considered impractical by the company. India faces substantial exposure as a major generic medicine exporter to the US.
Read at Times of India →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/b075727cc5788623c1139dbe2132582078877c29"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's"></iframe>

Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

How 1 sources are covering this

Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

More from US

Samsung Galaxy S26 Plus gets Rs 40,000 price cut on Amazon

iPhone 15 available at the lowest price: Full details

iPhone 17 available for Rs 53,000 on Flipkart: Checkout the deal

Samsung Galaxy S25 FE price drops to the lowest: Know the deal

Reader

Trust & legal

Across the network